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PURPOSE: There is evidence that female sex hormones impact caffeine metabolism, 
with decreased CYP1A2 activity and diminished caffeine clearance in women with 
higher estrogen levels. Therefore, the objectives of this project were to determine 
the effects of oral contraceptives and menstrual cycle on the benefits of caffeine 
supplementation for cycling performance. METHODS: Sixteen recreationally trained 
female cyclists, oral contraceptive steroid (OCS) users (n=8, age = 21.4 ± 1.4 years, 
height = 168.4 ± 3.6 cm, weight = 63.6 ± 7.2kg, VO2max = 48.0 ± 4.0 mlkg-1min-1) 
and non-users (n=8, age = 20.9 ± 2.1 years, height = 161.0 ± 7.7 cm, weight = 59.5 ± 
9.2 kg, VO2max = 50.9 ± 7.8 mlkg-1min-1), completed four separate computer-
simulated 3-km cycling time trials (TT). Subjects ingested either 6mg/kg of caffeine 
or a placebo capsule one hour prior to each trial. Magnitude based inferences were 
used to evaluate treatment differences. RESULTS: Caffeine enhanced 3-km TT 
performance (compared to placebo) in early and late phases of the menstrual cycle 
for OCS users ‘possibly’ and ‘very likely’ by 1.6 ± 2.1%, 2.7 ± 1.4% and non-users 
‘likely’ by 2.6 ± 2.3%, 2.1 ± 2.2% respectively. All other comparisons for OCS users 
and non-users were ‘unclear’. CONCLUSIONS: Caffeine supplementation improved 
3-km TT finishing time and average power output in follicular and luteal phases of 
the menstrual cycle, with unclear differences between the phases for both OCS users 
and non-users.  This indicates that menstrual status is not a significant source of 






Caffeine (1,3,7-trimethylxanthine) is often consumed for its stimulating effects and 
ability to improve physical performance (6). There is good evidence that caffeine 
supplementation can enhance physical performance ranging from peak strength to 
endurance performance (4–6, 11, 16, 21, 23, 55, 57, 61, 62).  Early research 
suggested that the ergogenic effect of caffeine on aerobic exercise stem from 
adrenaline-augmented free-fatty acid oxidation and glycogen sparing (13). Recently, 
the physiological responses to exercise altered by caffeine are suggested to be 
through stimulation of the central nervous system mediated by antagonizing 
adenosine receptor sites (51), which increases motor-unit recruitment in large 
muscle groups (5, 60) and reduces the rate of perceived exertion during endurance 
exercise (5, 6, 13, 17).  It is also accepted that caffeine binds to adenosine receptors 
limiting the relaxation of smooth muscles and vasodilation in the visceral organs in 
order to increase blood to the muscles (19).  
The optimal caffeine dose for performance benefits is between 3 and 6 mg of 
caffeine per kilogram of body mass (14, 21, 23, 57). Higher doses of ≥ 9 mg/kg do 
not result in further performance enhancement (21), and may even impair 
performance due to various side effects (i.e. tachycardia, anxiety, dizziness, nausea) 
(15, 23, 51).  The pharmokinetics of caffeine is predominantly regulated by hepatic 
cytochrome P450 (CYP1A2), the enzyme responsible for metabolizing the majority 
of caffeine (18, 39, 46, 47, 58, 65). Therefore, different concentration/activity levels 
of CYP1A2 represents a major source of variability in the pharmacokinetics of 
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caffeine (64), and consequently the dose-response. The enzyme-saturating dose of 
caffeine has been shown to be 6 mg/kg (39), suggesting that this dosage reaches the 
upper limit of hepatic caffeine metabolism, which is in line with the aforementioned 
dose-performance response relationship. 
CYP1A2 is involved in the biotransformation of drugs such as caffeine, along with 
being involved in the bioactivation of pro-carcinogens such as estradiol (33). 
Demethylation is the first step to caffeine metabolism (31). The three 
dimethylxanthine metabolites can be measured in plasma as done in time-
concentration studies (1, 3, 31, 34, 39, 53). Of the three dimethylxanthine 
metabolites, paraxanthine (1-7 dimethylxanthine) is more abundant than 
theobromine (3,7-dimethylxanthine) and theophylline (1-3-dimethylxanthine)(31, 
37); approximately 70-80% of caffeine is converted to paraxanthine (47). Less is 
known about paraxanthine kinetics and its potential role in facilitating beneficial 
effects of caffeine on exercise performance (11), however, caffeine metabolites have 
an even higher affinity for the adenosine receptors (12, 19), thereby plausibly 
having an even greater effect on performance than caffeine itself. This indicates that 
the rate of caffeine metabolism and consequential metabolite levels could be an 
important factor in the ergogenic properties of caffeine. Previous evidence 
observing the influence of genotype on caffeine metabolism suggests caffeine affect 
those who have faster caffeine metabolism to a greater degree within cycling 
performance, which was thought to be due to higher levels caffeine metabolites 
(63). This was thought to be due to caffeine metabolites. Indeed, several studies 
have reported that specific variations of the CYP1A2 enzyme that impact enzyme 
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levels are linked to caffeine-related performance and health outcomes (22, 25, 27, 
43, 63). 
Directly relevant to the rationale for the current project is that the vast majority of 
what is known about the impact on caffeine on performance and physiology has 
been derived from males (6, 11, 14, 20, 23, 35, 40, 54, 61, 63). Moreover, the little 
that is known about females in this context suggests that there may be sex specific 
responses to caffeine intake (10, 20, 36, 38). The rate of caffeine metabolism is not 
only sensitive to genetic variations of the enzyme, but also biological sex (6, 31); 
specifically, female sex hormones, estrogen and estradiol (1, 3, 18, 24, 48). There is 
an evident trend for higher plasma caffeine and lower plasma paraxanthine 
concentrations in women compared to men, suggesting that women metabolize 
caffeine slower than men (7). Women with higher estrogen levels, [such as oral 
contraceptive steroid (OCS) users, females in the luteal phase, or pregnant], have 
been found to have decreased CYP1A2 activity and decreased caffeine clearance (3, 
34, 48).  Despite the varying clearance rates across the menstrual cycle, currently 
nothing is known about whether or not this impacts the performance response to 
caffeine intake. Therefore, one of the primary aims of this study was to test the 
hypothesis that there will be a magnified effect of caffeine on performance in the 
follicular phase compared to the luteal phase. 
The use of hormonal contraceptives is another condition when estrogen levels are 
elevated, (56), possibly effecting the ergogenic effect of caffeine through dampening 
the rate of caffeine metabolism. OCS’s can diminish elimination kinetics of several 
drugs, including caffeine (53). OCS’s containing ethinyl-estradiol/estradiol/estrogen 
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are commonly used by young females as birth control and as treatment for female 
athlete triad to prevent bone loss (52), and to treat menstrual disturbances (32, 52). 
Chronic OCS use has been previously associated with impaired metabolism of 
caffeine (1, 3, 46, 49, 53, 59). There is evidence of delayed caffeine clearance in as 
little as the first two weeks of starting OCS use (53). Caffeine half-life was 
significantly prolonged (94% longer) in women on OCS as compare to nonusers 
(46). A 3-5.5 hour half-life of caffeine is common, however women on OCS’s may 
experience increased half-life to approximately 10 hours (7, 34). It is commonly 
reported that OCS’s inhibit CYP1A2 activity (1, 3, 26, 49, 50, 59). Whether the 
mechanism of CYP1A2 inhibition by estradiol is due to competition or down-
regulation of enzyme synthesis is unclear (8, 48).  OCS’s appear to modify the 
metabolism of caffeine by reducing the formation of paraxanthine, which is the 
primary pathway of caffeine metabolism, possibly limiting its physiological effects 
(50). 
The rate at which caffeine is absorbed by the gastrointestinal tract and reaches peak 
concentrations in the blood (≈ 60 minutes) is similar for OCS users and non-users 
(1, 39, 46). This finding indicates that absorption of caffeine and availability of 
plasma caffeine is not altered by OCS use, solely the breakdown of caffeine into its 
metabolites is affected.  Regardless of the implicit compounding effects of OCS use 
on caffeine metabolism, there is no current evidence of the interactive effect OCS use 
has on the ergogenic effect of caffeine. Therefore, the second aim of this project is to 
test the influence of OCS use on the performance response to caffeine 




Despite good evidence that caffeine enhances performance, data among female 
participants is sparse. Menstrual status is acknowledged as a contaminate of 
caffeine metabolism, but is avoided within performance studies as females are 
compared within the same phase, often the early follicular phase (10, 56). Moreover, 
the effect that oral contraceptives have on caffeine metabolism has led to the 
exclusion of oral contraceptive users in studies examining the effects that caffeine 
and caffeine metabolism have on performance. To our knowledge, nothing is known 
about how oral contraceptive use may influence the ergogenic effect of caffeine. The 
purpose of this study is to determine the effect of oral contraceptive use on caffeine 
metabolism and performance following caffeine consumption. Additionally, this 
study will yield further insight to the factors that can effect performance 
improvement in regards to caffeine ingestion including oral contraceptives and 




Aims and Hypotheses: 
Aim 1: To determine if the phase of the menstrual cycle mediates the effects of 
caffeine supplementation on 3k cycling performance time. 
Hypothesis 1: Caffeine will elicit a greater improvement in cycling performance time 
during the follicular phase compare to the luteal phase.  
Aim 2: To determine if oral contraceptive steroid use mediates the effects of caffeine 
consumption on 3k cycling performance times.  
Hypothesis 2: Caffeine will elicit a greater improvement in cycling performance time 






Thirty recreationally trained female cyclists from James Madison University 
and the greater Harrisonburg/ Rockingham County area will be included in this 
study. Inclusion criteria include: female, 18-35 years of age, non-smokers, cycle ≥ 30 
minutes at least two days a week, and VO2max ≥ 40 ml/kg/min. Further, subjects 
must be eumenhorreic with menstrual cycle length between 21-35 days over the 
past 6 months. Subjects who are not on any form of contraception will be assigned 
to the control group (n=15), and the subjects on monophasic or tri-phasic oral 
contraceptives will be assigned to the OCS user group (n=15). In the OCS user group, 
subjects will limited to monophasic oral contraceptives or tri-phasic oral 
contraceptives containing ethinyl estradiol and levonorgesterel for at least 6 months 
(9). Subjects will be fully informed about the experimental procedures and possible 
risks before given written informed consent. Informed consent includes information 
of the experimental procedures and risks prior to participation. James Madison 
University Institutional Review Board approved this study. 
Experimental Design 
Subjects will report to the laboratory for two familiarization trials and four 
experimental trials. Two experimental trials (1 placebo and 1 caffeine) will be 
conducted during the luteal phase and two experimental trials (1 placebo and 1 
caffeine) will be performed in the follicular phase of the menstrual cycle. The 
follicular phase trials will be performed from days 7 to 13 of the menstrual cycle, 
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and the luteal phase trials will be performed from days 18 to 24. Each treatment 
trial will be performed in the morning between 6:00am and 10:00am. Trials will be 
separated by at least 48 hours.  
Preliminary Testing 
Following height and body mass measurements, VO2max will be assessed 
during an incremental test on a bicycle ergometer (Velotron™ cycle ergometer, 
Racermate, Inc. Seattle, WA, USA). Workload will begin at 50 W and will be 
increased in 25 W increments every minute until volitional fatigue, or pedaling rate 
drops below 50 rpm for >10 seconds. Breath samples will be collected and oxygen 
consumption will be analyzed with a Moxus® Modular Metabolic System (AEI 
Technologies, Pittsburgh, PA, USA).  VO2max will be determined as the highest 30 
second mean oxygen uptake value.  
Supplementation 
In a crossover, double-blind design, subjects will be provided caffeine 
treatment or placebo. Anhydrous caffeine at 6mg/kg body weight will be measured 
into opaque gelatin capsules. For placebo pills, gluten-free rice flour will be put into 
opaque gelatin capsules. Supplementation will be ingested with water, 60 minutes 
prior to the performance trial.  
Familiarization Trials 
Two familiarization trials will be completed on a Velotron™ cycle ergometer 
before each subjects begins experimental trials. A 5-min warm-up will be performed 
before all 3-km time-trials. Subjects will be instructed to approach the time trial as a 
competition, emphasizing the importance to perform each trial as a race and put 
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forth 100% effort. All trials will be completed without verbal feedback and only 
elapsed distance will be displayed.  The familiarization trial protocol will be 
identical to the performance trials with the exception of caffeine/placebo 
supplementation. 
Performance Trials 
Subjects warmed up on a treadmill for 5 minutes at 3.5 mph, followed by the 
3k-time trial on a Velotron cycle ergometer. Performance will be recorded in time to 
complete and average watts for the 3-km time trial. 
Dietary and Exercise Control 
Subjects will complete 24-hour food logs and be instructed to replicate their 
diet for 24 hours prior to each subsequent trial. Subjects will be asked to refrain 
from any food or drink (besides water) for four hours before and from caffeine and 
alcohol for 12 hours before each trial.  The OCS user group will be required to 
authenticate intake of their respective oral contraceptive within the past 24 hours. 
In addition, 48-hour physical activity logs will be completed prior to each trial, and 
will be instructed to maintain consistent exercise habits between trials. Subjects will 
be asked to refrain from any vigorous physical activity 12 hours prior to each trial.  
Statistical Analysis 
Magnitude-based inferences about the data will be derived using methods 
described by Hopkins and colleagues (29). The smallest worthwhile change in 
performance was defined as 0.3 × the within-subject variability of select groups of 
elite cyclists across repeated time trials (CV = 1.3% for time and estimated 3.25% 
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for power), which translated to a difference in mean power output of 1% or 1.7 
watts and 0.4% or 1.4 seconds in the current project (45).   
A published spreadsheet by Hopkins (28) will then be used to determine the 
likelihoods of the true treatment effect of the population reaching the substantial 
change threshold (0.2 x CV); these will be classified as <1% = almost certainly no 
chance, 1-5% = very unlikely, 5-25% = unlikely, 25-75% = possible, 75-95% = likely, 
95-99% = very likely, and >99% = almost certain.  Clinical inference criteria were 
used to classify the effects of treatment on performance. Specifically, if the percent 
chance of the effect reaching the substantial change threshold was <25% and the 
effect was clear, it was classified as “trivial.” If the percent chance of the effect 
reaching the substantial change threshold for benefit exceeded 25% but the chance 
for harm was >0.5% the effect was classified as unclear. An exception to the 0.5% 
chance of harm criterion was made if the benefit/harm odds ratio was >66, in which 
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PURPOSE: There is evidence that female sex hormones impact caffeine metabolism, 
with decreased CYP1A2 activity and diminished caffeine clearance in women with 
higher estrogen levels. Therefore, the objectives of this project were to determine 
the effects of oral contraceptives and menstrual cycle on the benefits of caffeine 
supplementation for cycling performance. METHODS: Sixteen recreationally trained 
female cyclists, oral contraceptive steroid (OCS) users (n=8, age = 21.4 ±1.4 years, 
height = 168.4 ± 3.6 cm, weight = 63.6 ± 7.2 kg, VO2max = 48.0 ± 4.0 mlkg-1min-1) 
and non-users (n=8, age = 20.9 ± 2.1 years, height = 161.0 ± 7.7 cm, weight = 59.5 ± 
9.2 kg, VO2max = 50.9 ± 7.8 mlkg-1min-1), completed four separate computer-
simulated 3-km cycling time trials (TT). Subjects ingested either 6mg/kg of caffeine 
or a placebo capsule one hour prior to each trial. Magnitude based inferences were 
used to evaluate treatment effects. RESULTS: Caffeine enhanced 3-km TT 
performance (compared to placebo) in early (‘possibly’) and late (‘very likely’) 
phases of the menstrual cycle for OCS users by 1.6 ± 2.1% and 2.7 ± 1.4% 
respectively. Likewise, caffeine enhanced 3-km TT performance in early and late 
(‘likely’) phases of the menstrual cycle for non-users by 2.6 ± 2.3% and 2.1 ± 2.2%. 
All other comparisons for OCS users and non-users were ‘unclear’. CONCLUSIONS: 
Caffeine supplementation improved 3-km TT finishing time and average power 
output in follicular and luteal phases of the menstrual cycle, with unclear effects 
between the phases for both OCS users and non-users.  This indicates that menstrual 
status is not a significant source of variability on the ergogenic effect of caffeine 




Caffeine is commonly consumed for its stimulating effects on the central 
nervous system and ability to improve physical performance (6). There is good 
evidence that caffeine supplementation can enhance physical performance ranging 
from peak strength to prolonged endurance performance (~150 minutes)(4–6, 11, 
16, 21, 23, 55, 57, 61, 62), with optimal dosing falling somewhere between 3 and 6 
mg of caffeine per kilogram of body mass (14, 21, 23, 57).  
Caffeine metabolism is predominantly regulated by hepatic cytochrome P450 
(CYP1A2), the enzyme responsible for metabolizing the majority of caffeine (18, 39, 
46, 47, 58, 65). Therefore, different concentrations/activity levels of CYP1A2 
represents a major source of variability in the pharmacokinetics of caffeine (64). 
Demethylation is the first step to caffeine metabolism, which is mostly metabolized 
to form paraxanthine (31). Less is known about paraxanthine kinetics and its 
potential role in facilitating beneficial effects of caffeine on exercise performance 
(11). However, caffeine metabolites have an even higher affinity for the adenosine 
receptors, which stimulate the central nervous system (12, 19), thereby plausibly 
having an even greater effect on performance than caffeine itself.  
The rate of caffeine metabolism is not only sensitive to genetic variations of the 
enzyme, but also biological sex (6, 31). Specifically, female sex hormones, estrogen 
and estradiol influence caffeine levels following supplementation (1, 3, 18, 24, 48). 
There is an evident trend for higher plasma caffeine and lower plasma paraxanthine 
concentrations in women compared to men, suggesting that women metabolize 
caffeine slower than men (7). Moreover, women with higher estrogen levels, [such 
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as oral contraceptive steroid (OCS) users, females in the luteal phase, or during 
pregnancy], have been found to have lower CYP1A2 activity and decreased caffeine 
clearance (3, 34, 48).   Whether the mechanism of CYP1A2 inhibition by estrogen is 
due to competition or down-regulation of enzyme synthesis is unclear (8, 48). 
Despite the varying clearance rates across the menstrual cycle, currently nothing is 
known about whether or not this impacts the performance response to caffeine 
intake. Therefore, one of the primary aims of this study was to test the hypothesis 
that there will be a magnified effect of caffeine on performance in the follicular 
phase compared to the luteal phase. 
In addition to menstrual phase, estrogen levels are also elevated with certain 
types of oral contraceptives, (56), conceivably altering the ergogenic effect of 
caffeine via an attenuated rate of caffeine metabolism. Chronic OCS use has been 
previously associated with impaired metabolism of caffeine (1, 3, 46, 49, 53, 59), 
and it is commonly reported that OCS’s inhibit CYP1A2 activity (1, 3, 26, 49, 50, 59). 
OCS’s appear to modify the metabolism of caffeine by reducing the formation of 
paraxanthine, which is the primary pathway of caffeine metabolism, possibly 
limiting its physiological effects (50). There is no current evidence of the interactive 
effect OCS use has on the ergogenic effect of caffeine. Therefore, the second aim of 
this project is to test the influence of OCS use on the performance response to 






Twenty-eight healthy, recreationally trained female cyclists (15 OCS users, 
13 non-users) from James Madison University and the greater Harrisonburg/ 
Rockingham County area volunteered for the study. However, seven OCS users and 
five non-users withdrew from the study due to injuries, Lyme disease diagnosis, 
switching birth control prescription, seasonal flu, vasovagal syncope, or scheduling 
difficulties.  
Inclusion criteria included: female, 18-35 years of age, non-smokers, cycle ≥ 
30 minutes at least two days a week, and VO2max ≥ 40.0 mlkg-1min-1. Further, 
subjects were required to be eumenhorreic with menstrual cycle length between 
21-35 days over the past 6 months. Descriptive data are shown in Table 1.  Subjects 
who were not on any form of contraception were assigned to the control group 
(n=8), and the subjects on monophasic or tri-phasic oral contraceptives were 
assigned to the OCS user group (n=8). In the OCS user group, subjects were limited 
to monophasic oral contraceptives or tri-phasic oral contraceptives containing 
levonorgesterel and ethinyl-estradiol for at least 6 months to ensure consistent 
levels of estradiol (9).  
Subjects were fully informed about the experimental procedures and 
possible risks before given written informed consent. Informed consent included 
information of the experimental procedures and risks prior to participation. James 





Subjects reported to the laboratory for two familiarization trials and four 
experimental trials. Two experimental trials (1 placebo and 1 caffeine) were 
conducted during the follicular phase and two experimental trials (1 placebo and 1 
caffeine) were performed in the luteal phase of the menstrual cycle. Experimental 
trials during the follicular phase were performed from days 7 to 13 of the menstrual 
cycle, and the luteal phase trials were performed from days 18 to 24. Menstrual 
status was not verified by secondary measures (i.e. estrogen levels, body 
temperature, etc.). As such, the presumed follicular and luteal phases will be 
referred to as ‘early’ and ‘late’ phases, respectively.  
Preliminary Testing 
Following height and body mass measurements, maximal oxygen 
consumption (VO2max) was assessed during an incremental test on a bicycle 
ergometer (Velotron™ cycle ergometer, Racermate, Inc. Seattle, WA, USA). Workload 
started at 50 W and was increased in 25 W increments every minute until volitional 
fatigue, or pedaling rate dropped below 50 rpm for >10 seconds. Breath samples 
were collected and oxygen consumption (VO2) was analyzed with a Moxus® Modular 
Metabolic System (AEI Technologies, Pittsburgh, PA, USA).  VO2max was determined 
as the highest 30 second mean oxygen uptake value.  
Supplementation 
In a crossover, double-blind design, subjects were provided caffeine 
treatment or placebo. Anhydrous caffeine (6 mg/kg body mass) was measured into 
opaque gelatin capsules. For placebo pills, gluten-free rice flour was put into opaque 
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gelatin capsules. Supplementation was ingested with water 60 minutes prior to the 
performance trial.  
Familiarization Trials 
Prior to the experimental trials, two separate familiarization trials were 
completed on a Velotron™ cycle ergometer. A 5-min self-selected warm-up was 
performed before all 3-km time-trials. Subjects were instructed to approach the 
time trial as a competition, emphasizing the importance to perform each trial as a 
race. All trials were completed without verbal feedback and only elapsed distance 
was displayed.  The familiarization trial protocol was identical to the performance 
trials with the exception of caffeine/placebo supplementation. 
Performance Trials 
The subjects performed a 5-min warm-up, followed by a computer-simulated 
3-km time trial on the Velotron cycle ergometer. Average power output during the 
time trial and finishing times were recorded and used as the performance measures.  
Dietary and Exercise Control 
Subjects completed 24-hour food logs and were instructed to replicate their 
diet for 24 hours prior to each subsequent trial. Subjects were asked to refrain from 
any food or drink (besides water) for four hours before and from caffeine and 
alcohol for 12 hours before each trial.  The OCS user group was required to 
authenticate intake of their respective oral contraceptive within the past 24 hours. 
In addition, 48-hour physical activity logs were completed prior to each trial, and 
subjects were instructed to maintain consistent exercise habits between trials. In 
addition, subjects were asked to refrain from any vigorous physical activity 12 
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hours prior to each trial. Each treatment trial was performed in the morning 
between 6:00am and 10:00am. Trials were separated by at least 48 hours. 
Statistical Analysis 
Magnitude-based inferences were derived using methods described by 
Hopkins and colleagues (29). The smallest worthwhile change in performance was 
defined as 0.3 × the within-subject variability of select groups of elite cyclists across 
repeated time trials (CV = 1.3% for time and estimated 3.25% for power), which 
translated to a difference in mean power output of 1% or 1.7 watts and 0.4% or 1.4 
seconds in the current project (45).   
A published spreadsheet by Hopkins (28) was used to determine the 
likelihoods of the true treatment effect of the population reaching the substantial 
change threshold; these were classified as <1% = almost certainly no chance, 1-5% = 
very unlikely, 5-25% = unlikely, 25-75% = possible, 75-95% = likely, 95-99% = very 
likely, and >99% = almost certain.  If the percent chance of the effect reaching the 
substantial change threshold was <25% and the effect was clear, it was classified as 
‘trivial’ effect.  If 90% confidence intervals included values that exceeded the 
substantial change threshold for both a positive and negative effect, effects were 
classified as unclear (>5% chance of reaching the substantial threshold for both a 








3-km Time Trial Performance 
In general, caffeine enhanced 3-km TT performance (compared to placebo) in 
OCS users and non-users in both menstrual phases. 3-km TT performance data 
(finishing time) are reported in Figure 1 and Table 2. In addition, the 3-km TT 
power output data (average wattage) are reported in Table 2.  
 For the non-user group, caffeine ‘likely’ improved performance time by 2.6 ± 
2.3% during the early phase and by 2.1 ± 2.2% in the late phase. Likewise, caffeine 
‘likely’ increased power output by 6.7 ± 6.1% in the early phase and ‘very likely’ 
increased power output by 6.7 ± 4.8% in the late phase. It was ‘unclear’ whether 
there were differences in the magnitude of benefit from caffeine between the early 
and late phases for finishing time and average wattage.   
Similarly for the OCS users, caffeine ‘possibly’ improved performance by 1.6 
± 2.1% during the early phase and ‘very likely’ improved performance by 2.7 ± 1.4% 
during the late phase. While, power output was ‘likely’ increased by 4.7 ± 5.6% in 
the early phase, and was ‘very likely’ increased by 7.2 ± 3.7% in the late phase.  
 When comparing finishing time for non-users and OCS users by average of 
both phases, the outcome is ‘unclear’ to whether non-users or OCS users benefitted 
more altogether.  
Discussion 
 The purpose of the current study was to investigate how two distinct phases 
of the menstrual cycle and the use of oral contraceptives influenced the ergogenic 
effects of caffeine on 3-km cycling performance.  The major finding was that caffeine 
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improved 3-km time trial performance for female cyclists during both the early and 
late phases of the menstrual cycle, with no clear difference between the early or late 
phase of the menstrual cycle. Further, oral contraceptive status (users vs. non-
users) did not appear to systematically influence the ergogenic effect of caffeine 
supplementation. The collective data suggest that menstrual status is not a 
significant source of variation in the performance response to caffeine 
supplementation.  
 While not measured in the current study, the concentrations of endogenous 
female sex hormones vary considerably during the menstrual cycle, with estradiol 
concentration in serum rising from 10-30 pg/ml in the follicular phase to 80-200 
pg/ml during the luteal phase (65). Given the prior evidence of slowed caffeine 
metabolism with higher levels of estrogen (3, 34, 48),  we suspected that high 
estrogen levels associated with the late menstrual phase (luteal) would slow 
caffeine metabolism. As a result, we hypothesized that non-OCS users would 
experience higher caffeine: metabolite levels following supplementation in the late, 
versus early phase, thus leading to a greater caffeine benefit. To our knowledge, this 
is the first study to investigate the menstrual phase as a possible source of the 
variation in the ergogenic effect of caffeine supplementation. Therefore it is not 
possible to compare to previous findings. However, the absence of a systematic 
difference in the performance benefit of caffeine between menstrual phases 
observed here is indirectly supported by prior studies indicating the males and 
females benefit similarly to caffeine ingestion (2, 10, 20). It may be that alterations 
in hepatic P-450 enzyme activity between phases of the menstrual cycle are not 
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physiologically relevant, as shown in drug therapy (65), Also noted by a meta-
analysis of the effect of the menstrual cycle on metabolism during exercise, a 
limitation to this study is the participation following an overnight fast, as a positive 
nutritional state may lessen the impact of ovarian hormones on metabolism during 
exercise (41).  Thus, the effect of estrogen on CYP1A2 enzyme activity may not be 
enough to influence the ergogenic effect of caffeine despite the fact that we tested 
subjects under dietary conditions that should have magnified the impact of 
estrogen. Estrogen may have less of an effect following usual dietary intake.  
Using the same logic outlined above, because we suspected that OCS users 
would have had higher estrogen levels than non-users, we therefore hypothesized 
OCS users would have slowed caffeine metabolism, thus lower caffeine: metabolite 
ratio leading to less benefit of caffeine compared to non-users. Again, in contrast to 
our hypothesis, there was no clear difference in the performance response to 
caffeine between OCS users and non-users. Therefore, the difference of estrogen 
levels in modern OCS may not compromise caffeine metabolism to a degree 
influences the ergogenic effect of caffeine. It is important to note that the outcome 
was ‘unclear’, which does not indicate consistent/similar responses between 
groups, but rather marked variability in the responses to caffeine. This suggests that 
more data needs to be gathered before drawing firm conclusions about potential 
differences.   
 It is well known that there is significant individual variability in the 
performance response to caffeine. Our laboratory, and others, have suggested that 
this variability may be related to differences in the rate of caffeine metabolism and 
23 
 
absorption between individuals (42, 44, 63). There is evidence that peak blood 
caffeine levels occur one hour after ingestion (4), and that these levels are similar 
for both OCS users and non-users (46). Thus we know absorption of caffeine is 
similar in OCS users and non-users, but rates of metabolism are highly variable. 
Therefore, we speculate that the difference in ergogenic effect of caffeine between 
these two groups would be greater beyond one hour post-ingestion, as the half-life 
of caffeine is prolonged in OCS users (46). Future research should consider 
evaluating performance more than one-hour post caffeine ingestion to establish the 
effect of caffeine metabolism rate, or caffeine and metabolite concentrations, on 
ergogenic effect of caffeine.  
One major limitation of the current study is the presumption of different 
estrogen levels between the early and late phases. Although there is strong evidence 
of diminished caffeine metabolism with high levels of estradiol (53), we have no 
measure to determine caffeine elimination kinetics within our sample.  In order to 
evaluate the influence of the menstrual cycle, it was essential to determine 
menstrual phases to keep hormone levels consistent within an investigation, which 
was done by examining women outside of the days of menses and the days of 
ovulation (where spikes in other female hormones, such as progesterone and 
follicular-stimulating hormone occur) (30, 56).  
The primary strength of this project was the concomitant investigation of 
oral contraceptive status and menstrual phase, two conditions that presumably 
impact estrogen levels, on the benefit that caffeine has on simulated performance. 
Unfortunately the outcomes from this investigation are considerably weakened by 
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the absence of blood estrogen measurements. Therefore, we cannot definitely 
conclude that estrogen levels, per se, do not alter the performance response to 
caffeine. Altogether, the results from this investigation indicate that females derive 
performance benefits from caffeine irrespective of menstrual phase and despite use 
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Table 1.0 Descriptive Data 
 Total (n=16) Non-Users (n=8) OCS Users (n=8) 
Height (cm) 164.7 ± 6.9 161.0 ± 7.7 168.4 ± 3.6 
Weight (kg) 61.2 ± 8.6 58.8 ± 9.7 63.6 ± 7.2 
Age (yrs) 21.1 ± 1.8 20.6 ± 2.1 21.4 ± 1.4 
VO2max (ml/kg/min) 49.7 ± 6.5 51.3 ± 8.2 48.0 ± 4.0 
Cycling (hrs/week) 3.1 ± 1.9 3.8 ± 2.0 2.4 ± 1.7 
Caffeine (mg/week) 601.1 ± 494.9 623.4 ± 551.1 578.9 ± 469.0 










Table 2. 3-km Performance Time and Power Output Data 
  
  
Mean ± SD 
Within-Condition Differences; ∆PLA vs. CAF 
Mean, ± 90%CI (raw) 
 % Likelihoods (+/triv/-), Inference 
Between-Condition 
Differences ∆Early vs. Late 
Mean, ± 90%CI (raw) 
 % Likelihoods (+/triv/-), 
Inference 
Variable Condition PLA CAF PLA vs. CAF 















358.9 ± 43.1 
(167.1 ± 51.6) 
349.9 ± 44.2 
(178.4 ± 52.5) 
2.6 ± 2.3, % likelihoods (2, 4, 94) likely 
beneficial 










356.8 ± 28.3 
(162.3 ± 28.5) 
351.0 ± 28.4 
(170.1 ± 31.8) 




356.3 ± 38.2 
(167.6  ± 47.9) 
348.2 ± 31.5 
(177.0 ± 41.4) 




354.7 ± 22.9 
(164.1 ± 24.5) 
345.0 ± 21.3 
(176.0 ± 27.0) 
2.7 ± 1.4, % likelihoods (0, 2, 98) very likely 
beneficial 
Values for Placebo (PLA) and Caffeine (CAF) reported as Mean ± SD. Comparison values reported Mean±90% CI for differences between change 





Figure 1 Average (mean ± SE) 3-km Time Trial performance for the caffeine and placebo 
treatments for non-oral contraceptive users and oral contraceptive users during the early 
and late phases.  
 
Effects of Caffeine during 3-km Time Trial performance in seconds: Bars depict mean time 
in seconds (± SE). (a) ‘Very likely’ improvement vs. placebo. (b) ‘Likely’ improvement vs. 
















































James Madison University 
Department of Kinesiology 
Consent for Investigative Procedure 
 
I, ______________________, hereby agree on _____________ (date) to participate in the research 
project conducted by Nicholas D. Luden, Ph.D., and Annette Lemanski from James Madison 
University titled The Effect of Oral Contraceptives on Caffeine Metabolism and Performance. 
 
The purpose of this study is to determine the impact of oral contraceptives on caffeine 




I understand that I will undergo the following testing in the study: 
 
This study consists of seven separate exercise tests performed on a stationary bike 
(cardiovascular fitness test, one familiarization test, and four 3km time trial tests). All testing 
will occur in Godwin Hall, room 209, on the campus of James Madison University. You will 
also be asked about lifestyle behaviors such as smoking and physical activity and oral 
contraceptive use and duration of use. The total time commitment is estimated to be less 
than 6 hours over the course of 8 weeks. 
 
Pre-testing 1 (60 min):  
 
After completing this consent form and the health history screening, if you meet the inclusion 
criteria for the study, researchers will measure your height and body weight. 
 
You will then be asked to perform a maximal cardiovascular fitness test to determine peak 
oxygen consumption (VO2max). You will be asked to ride a stationary bike at an initial 
workload that is ‘fairly easy’. The workload will then be increased every two minutes until 
exhaustion is reached, determined by either: 1) your request to stop due to fatigue, or 2) 
inability to maintain a cadence of ≥50 revolutions per minute. You will be verbally 
encouraged to continue to obtain an accurate measurement of VO2max. To access oxygen 
consumption, you will need to breathe through a mouthpiece/breathing apparatus which 
collects expired air throughout the test (10-15 minutes). 
 
 
Familiarization Trials (n =2; 30 minutes):  
 
On one occasion, you will be asked to perform a 3-km cycling practice trial on a stationary 
bike. You will warm-up with a 5-minute treadmill test at 3.5 mph, followed by the stationary 
bicycle 3-km time trial. You will be encouraged to treat the time trial like a competition. 




You will report to the laboratory 60 minutes prior to exercise testing. You will rest in a seated 
position for 5 minutes, after which a blood sample will be obtained for measurement of 
caffeine levels (one of the samples will also be used to extract DNA for genotyping). 
Immediately following the blood draw, you will ingest either placebo or caffeine capsules, 
after which you will wait for ~60 minutes in the laboratory until exercise testing. 
Immediately prior to exercise testing, a second blood sample will be obtained for the 
measurement of caffeine levels. Following the blood draw, you will complete the 3-km time 
trial described above.  
 
Supplementation Protocol: 
No supplementation will be given during the familiarization trial. You will be randomly 
assigned a treatment order. Treatments will be: 1. Placebo capsule containing flour 
administered 1hr prior to exercise between 6-10am 2. Caffeine capsule containing 6 
mg/kg bodyweight caffeine administered 1hr prior to exercise between 6-10am. 
 
DNA Sampling: 
We will extract a sample of your DNA from one of your blood samples to determine the type 
of enzyme that you have to breakdown caffeine. DNA and blood samples will be stored in our 
laboratory freezer indefinitely to allow us to conduct follow-up studies in the event that new 
discoveries are made related to DNA and caffeine metabolism. Your sample will be destroyed 
immediately upon request. Your sample will be coded so that nobody except the primary 
investigators can identify which sample is yours. The DNA testing will involve determining 
sequences of DNA for specific genes that are related to caffeine metabolism. We will not use 
this DNA for any other purpose.  The results of this genetic testing will only be available to 
the primary investigator and you. These results will not be made public and will be stored in 




Cardiovascular Exercise (3-km Time Trial and VO2max test) 
 
According to the American College of Sports Medicine’s Guidelines for Exercise Testing and 
Prescription, the risk associated with heavy exercise for individuals categorized as “low risk” 
is very minimal, and physician supervision is not necessary.  The conditions that the exercise 
sessions are to take place are likely safer than the typical exercise environments of the 
subjects. If you do not meet ACSM criteria for “low risk”, you will not be allowed to participate 
in the study. In the unlikely event of cardiac or other complications during exercise, an 
emergency plan is in place. This includes immediate access to a phone to call emergency 
personnel. In addition, at least one of the listed investigators will be present during the 







The risks of blood sampling using venipuncture include possible mild bruising, and the risk 
of transfer of blood-borne pathogens, as well as possible risks of infection or skin irritation.  
These risks are considered to be minimal, and all safety precautions for handing blood 
samples will be followed according to OSHA protocols, including: investigators will wear 
latex gloves at all times during blood sampling and testing. A sharps container lined with a 
biohazard bag will be used for all sharp objects involved in the blood sampling; all other 
materials (i.e. gloves, gauze pads, etc.) used during the sampling will be put in a separate 
waste disposal unit lined with a biohazard bag. All investigators who will be involved in 
blood draws (and handling of blood) have been trained in these phlebotomy techniques, and 
completed JMU blood-borne pathogen training. The total amount of blood obtained during 
this study is approximately 25 ml. For reference, this amount is ~ 6% of a can of soda, or 5% 




The risks and side effects associated with caffeine supplementation include: rapid heart rate, 




The top 10 performers will be entered into a drawing to win a $150 and $75.  
 
Confidentiality  
The results of this research will be presented at conferences and published in exercise 
science journals.  The results of this project will be coded in such a way that your identity 
will not be attached to the final form of this study.  The researcher retains the right to use 
and publish non-identifiable data.  However, you can ask that your data be removed from the 
study at any point prior to presentation and publication.  While individual responses are 
confidential, aggregate data will be presented representing averages or generalizations 
about the responses as a whole.  All data will be stored in a secure location accessible only 
to the researcher.  Final aggregate results will be made available to you upon request. 
Participation & Withdrawal  
Your participation is entirely voluntary.  You are free to choose not to participate.  Should 
you choose to participate, you can withdraw at any time without consequences of any kind.  
Your right to withdraw includes the right to request that your DNA and blood samples be 
discarded at any time.  You should be aware that the DNA sample is subject to court 
subpoena. To dispose of your samples, your samples will be rinsed down a chemical drain in 
our laboratory or will be disposed of in a biohazard container. Again, your sample will not 







You may have questions or concerns during the time of your participation in this study, or 
after its completion.  If you have any questions about the study, contact Annette Lemanski, 
lemansam@dukes.jmu.edu. Or by phone (715) 340- 4423 
 
Giving of Consent 
I have read this consent form and I understand what is being requested of me as a participant 
in this study.  I freely consent to participate.  I have been given satisfactory answers to my 
questions.  The investigator provided me with a copy of this form.  I certify that I am at least 
18 years of age. 
 
   
Name of Participant  (Printed)  Name of Researcher(s)  (Printed) 
   
Name of Participant  (Signed)  Name of Researcher(s)  (Signed) 
   
  Date    Date 
 
For questions about your rights as a research subject, you may contact the chair of JMU’s 











AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire 
Assess your health status by marking all true statements 
 
History 
You have had: 
   a heart attack 
   heart surgery 
   cardiac catheterization 
   coronary angioplasty (PTCA) 
   pacemaker/implantable cardiac 
   defibrillator/rhythm disturbance 
   heart valve disease 
   heart failure 
   heart transplantation 
   congenital heart disease 
 
Symptoms 
   You experience chest discomfort with exertion 
   You experience unreasonable breathlessness 
   You experience dizziness, fainting, or blackouts 
   You take heart medications 
 
Other Health Issues 
   You have diabetes 
   You have asthma or other lung disease 
   You have burning or cramping sensation in your lower  
   legs when walking short distances 
   You have musculoskeletal problems that limit your  
   physical activity 
   You have concerns about the safety of exercise 




Cardiovascular risk factors 
   You are a man older than 45 years 
   You smoke, or quit smoking within the previous 6 months 
   Your blood pressure is > 140/90 mmHg 
   You do not know your blood pressure 
   You take blood pressure medication 
   Your blood cholesterol level is > 200 mg/dl 
   You do not know your cholesterol level 
   You have a close blood relative who had a heart attack or 
   heart surgery before age 55 (father or brother) or age 65 
       (mother or sister) 
   You are physically inactive (i.e. you get < 30 minutes of  
   physical activity on at least 3 days of the week) 
   You are > 20 pounds overweight 
 
 
   None of the above 
 
 
If you marked any of these 
statements in this section, consult 
your physician or other appropriate 
health care provider before 
engaging in exercise.  You may need 
to use a facility with a medically 
qualified staff. 
If you marked two or more of the 
statements in this section, you 
should consult your physician or 
other appropriate health care 
provider before engaging in 
exercise.  You might benefit from 
using a facility with a 
professionally qualified exercise 
staff to guide your exercise 
program. 
You should be able to exercise safely 
without consulting your physician 
or other appropriate health care 
provider in a self-guided program or 
almost any facility that meets your 









Height: __________ Weight: __________ 
 
Typical Exercise Habits over the past 3 months 
 
Average number of days cycling per week: ________ 
 
Average number of hours cycling per week: ________ 
 
 




Are you allergic tor rice flour? 
 
 
Are you allergic to latex? 
 
Contraceptive use:  
 
Are you currently on any form of contraceptives (including the ring, IUD, etc)?  
 
Are you currently using oral contraceptives? 
 
 If yes, what is the brand name of your current medication? 
 
 
 How long have you been using oral contraceptives? 
 
Approximately how long is your menstrual cycle (in days)? Menstrual cycle is day one 









Please list your approximate weekly intake of the following: 
 
Cups of coffee: 
 
Cups of tea: 
 
Cans (12oz) caffeinated soda: 
 
Servings of chocolate:  
 
Doses of caffeinated pills:  
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